https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-912012-08-21 00:00:002019-02-15 08:52:22Immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-20 / Oncologist 2012;17(10):1256-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-20 / Oncologist 2012;17(10):1256-702012-08-20 00:00:002019-02-15 08:39:54NK cells: key to success of DC-based cancer vaccines?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-352012-08-19 00:00:002019-02-15 09:22:38The use of oncolytic viruses to overcome lung cancer drug resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-72012-08-10 00:00:002019-02-15 08:53:36Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-602012-08-09 00:00:002019-02-15 08:53:37Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-82012-08-07 00:00:002019-02-15 08:48:47Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):352012-08-01 00:00:002012-08-01 00:00:00Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-912012-08-01 00:00:002012-08-01 00:00:00Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-302012-08-01 00:00:002019-02-15 09:21:33Newcastle disease virus: a promising agent for tumour immunotherapy
